Tesamorelin

Last Updated: August 2026

Tesamorelin is a synthetic 44-amino-acid GHRH (growth hormone-releasing hormone) analog FDA-approved as Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It was approved by the FDA in 2010 and is the only GHRH analog with an active FDA-approved obesity-adjacent indication. Research-grade tesamorelin is also sold by third-party laboratories for laboratory use only — that material is not the FDA-approved prescription product.

What is tesamorelin and how does the GHRH-analog mechanism work?

Tesamorelin is human GHRH(1-44) with an N-terminal trans-3-hexenoic acid modification that resists DPP-4 degradation, stimulating pituitary GH release through binding to the GHRH receptor. Unlike GHRP/ghrelin-receptor agonists like ipamorelin, tesamorelin acts upstream on the GHRH axis, preserving pulsatile GH secretion patterns. The mean elimination half-life is about 8 minutes per the current US label (EGRIFTA SV, single subcutaneous dose in healthy subjects) — short enough that daily subcutaneous dosing maintains physiological GH pulses without saturating receptors.1 source Evidence level: Human RCT (Phase 3 for HIV-associated lipodystrophy).

What does the Phase 3 evidence show for tesamorelin?

In the two Phase 3 trials for HIV-associated lipodystrophy, tesamorelin 2 mg daily reduced visceral adipose tissue by approximately 11–15% at 26 weeks versus placebo, and reductions were maintained with continued treatment — approximately 18% below baseline at 12 months in the extension analysis.2 sources IGF-1 levels increased modestly, with monitoring required to keep them within physiological range. Outside the FDA indication, tesamorelin has been studied in NAFLD (non-alcoholic fatty liver disease) and HIV-associated cognitive impairment with promising but not yet pivotal data. Evidence level: Human RCT (Phase 3 for HIV lipodystrophy; Phase 2 for other indications).

How does tesamorelin compare to sermorelin and CJC-1295?

Tesamorelin, sermorelin, and the CJC-1295 family are all GHRH analogs but differ on half-life, FDA status, and target indication. Tesamorelin's modification provides extended half-life via DPP-4 resistance; sermorelin uses the unmodified GHRH(1-29) sequence with shorter activity; CJC-1295 with DAC dramatically extends half-life via albumin binding for weekly dosing.

What are the documented side effects of tesamorelin?

The most common tesamorelin side effects in the Egrifta pivotal trials were injection-site reactions (17% vs 6% on placebo — erythema, pruritus, rash, pain and related events combined), arthralgia (13% vs 11% on placebo), peripheral edema, and elevated IGF-1.1 source Glucose intolerance and new-onset diabetes are monitored signals; tesamorelin can reduce insulin sensitivity in some patients, particularly those with pre-existing risk factors. Discontinuation rates in trials were low. The full safety dataset is in the Egrifta prescribing information. Evidence level: Human RCT (Phase 3); FDA prescribing information.

What is the regulatory status of tesamorelin?

Tesamorelin is FDA-approved as Egrifta (2010) for HIV-associated lipodystrophy, with the Egrifta SV reformulation approved in 2019. The trials and original approval used the 2 mg dose; the EGRIFTA SV dose is 1.4 mg of the reformulated product, and a newer formulation, EGRIFTA WR, is also on the current US label (as of August 2026).1 source It is available by prescription through specialty pharmacies. Research-grade tesamorelin sold by third-party laboratories is not the FDA-approved prescription product — that material is supplied for research use only and does not carry pharmacy-grade quality controls. For prescription-vs-research-grade context, see peptide regulatory status by country.

Why does tesamorelin vendor verification matter even though Egrifta is FDA-approved?

Because the FDA approval applies to the prescription Egrifta product — not to research-grade tesamorelin sold by third-party labs, which is a separate supply chain with its own quality risks. Research-grade material is subject to wider purity variance, occasional underdosing, and inconsistent endotoxin control. Independent HPLC purity testing and mass spectrometry identity confirmation are the only meaningful purity signals a research-grade vendor can provide. Guidance in how-to-test-peptides hub.

How does Peptigrity verify tesamorelin vendors?

Peptigrity collects independent third-party Certificates of Analysis for tesamorelin from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently Asked Questions

How can I verify a tesamorelin vendor is selling real product?

The only reliable purity signal is an independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay. Peptigrity publishes independent tesamorelin test results from independent labs in the table above. For COA interpretation, see red flags in peptide certificates of analysis.

Is research-grade tesamorelin legal to purchase?

Research-grade tesamorelin is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption and is not the FDA-approved prescription product Egrifta. Country breakdown in peptide legal status guide.

Why is tesamorelin researched for visceral fat specifically?

Tesamorelin's FDA approval is specifically for visceral adipose tissue (VAT) reduction in HIV-associated lipodystrophy, where excess abdominal fat is a documented complication. GH and IGF-1 elevation preferentially mobilize visceral fat over subcutaneous, which is why GHRH-analog approaches have been studied for VAT-specific reduction outside the HIV indication as well.

How does tesamorelin compare to GLP-1 weight-loss compounds?

Tesamorelin produces visceral-fat-specific reduction through GH/IGF-1 axis elevation; GLP-1 compounds like semaglutide or tirzepatide produce broader weight loss through appetite suppression and metabolic modulation. They are not mechanistically interchangeable; tesamorelin's effects on overall body weight are modest, while GLP-1 compounds drive larger total weight reductions.

Does Peptigrity recommend a tesamorelin dose?

No. Peptigrity is an independent review platform, not a medical authority — and research-grade tesamorelin is not approved for human consumption. The FDA-approved Egrifta dose for HIV-associated lipodystrophy is 2 mg subcutaneous daily, administered under physician supervision with IGF-1 monitoring. Anyone considering tesamorelin should consult a licensed physician.

Does tesamorelin show up on a drug test?

Tesamorelin and other GHRH analogs are on the WADA Prohibited List (Section S2 — Peptide Hormones) and competitive athletes face sanctions for use. Detection methods for GHRH analogs in anti-doping testing have improved substantially. For broader drug-testing context, see do peptides show up on drug tests.

This section is for educational and informational purposes only and does not constitute medical advice. Research-grade tesamorelin sold for laboratory use is not the FDA-approved prescription product (Egrifta). Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.